JRC Publications Repository

JRC Publications Repository >

Browsing by Author APOSTOLIDIS Christos

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 81 to 100 of 139
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2012Non-aqueous Synthesis of Isotropic and Anisotropic Actinide Oxide NanocrystalsHUDRY DAMIEN; APOSTOLIDIS Christos; WALTER OLAF; GOUDER Thomas; COURTOIS Eglantine; KUEBEL Christian; MEYER D.Articles in Journals
2007Non-invasive Visualisation of the Development of Peritoneal Carcinomatosis and Tumour Regression After 213Bi-radioimmunotherapy Using Bioluminescence ImagingBUCHHORN H.m.; SEIDL C.; BECK R.; SAUR D.; APOSTOLIDIS CHRISTOS; MORGENSTERN ALFRED; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2012Orthotopic administration of 213Bi-Bevacizumab inhibits progression of PC3 xenografts in the prostateRIZVI S.m.a.; ALLEN B.j.; LEE C.s.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; APOSTOLIDIS Christos; CLARKE R.a.Articles in Journals
1996Oxo-Bridged Bimetallic Organouranium Complexes. The Crystal Structure of nu-Oxo-Bis[Tris(Cyclopentadienyl)Uranium]SPIRLET M.r.; REBIZANT Jean; APOSTOLIDIS Christos; DORNBERGER Ernst; POWIETZKA B.Articles in Journals
2007Pharmacokinetics and toxicity of 213Bi-labeled PAI2 in Preclinical Targeted Alpha Therapy for CancerSONG E.; ABBAS RIZVI S. M.; QU C. F.; RAJA C.; BRECHBIEL M. W.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; ALLEN B. J.Articles in Journals
2005Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic CancerQU C.f.; SONG E.; LI Y.; RIZVI S.m.a.; RAJA C.; ROSS R; APOSTOLIDIS CHRISTOS; ALLEN Barry J.; MORGENSTERN ALFREDArticles in Journals
2006Preclinical Studies of Bismuth-213 Labeled Plasminogen Activator Inhibitor Type 2 (PAI2) in a Prostate Cancer Nude Mouse Xenograft ModelRIZVI S.m.a.; LI Y.; SONG E.; QU C.f.; RAJA C.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; ALLEN B.j.Articles in Journals
2008Preparation and Testing of Bevacizumab Radioimmunoconjugates with Bismuth-213 and Bismuth-205 / Bismuth-206RIZVI S.; SONG E.; RAJA C.; BERETOV J.; MORGENSTERN Alfred; APOSTOLIDIS Christos; RUSSELL P. J.; KEARSLEY J.; ABBAS Kamel; ALLEN B. J.Articles in Journals
2008Production of 230U/226Th for Targeted Alpha Therapy via Proton Irradiation of 231PaMORGENSTERN Alfred; LEBEDA O.; STURSA J.; BRUCHERTSEIFER Frank; CAPOTE R.; MCGINLEY John; RASMUSSEN Gert; SIN M.; ZIELINSKA B.; APOSTOLIDIS ChristosArticles in Journals
1998Production of Ac-225 and Application of the Bi-213 Daughter in Cancer Therapy.KOCH Lothar; APOSTOLIDIS Christos; JANSSENS Willem; VAN GEEL Jacobus; MOLINET RogerContributions to Conferences
2005Production of Ac-225 from Th-229 for Targeted Alpha TherapyAPOSTOLIDIS CHRISTOS; MOLINET Roger; MORGENSTERN ALFREDArticles in Journals
2008Production of Alpha Emitters for Targeted Alpha TherapyMORGENSTERN Alfred, et alArticles in Journals
2008Production of Alpha Emitting Radionuclides for Nuclear MedicineMORGENSTERN Alfred, et alArticles in books
2001Production of Carrier Free Actinium-225/Bismuth-212 from Thorium-229 for alpha-Immunitherapy.APOSTOLIDIS Christos, et alContributions to Conferences
2009Radioimmunotherapy of Breast Cancer Metastases with Alpha-Particle-emitter 225Ac: Comparing Efficacy with 213Bi, 90YSONG Hong, et alArticles in Journals
2009Radioimmunotherapy of human bladder cancer in a nude mouse model comparing Bi-213-anti-EGFR-MAb and Th-226-anti-EGFR-MAbPFOST B., et alContributions to Conferences
2001Radiopeptide Therapy with Cholecystokinin(CCK)-B/Gastrin Receptor Ligands Labeled with Auger/Conversion Electron-versus alpha- or Conventional beta Emitters.BEHR T.m., et alContributions to Conferences
2000Radiopeptide Therapy with Cholecystokinin-B/Gastrin Receptor Ligands: Dose-Limiting Toxicity and Therapeutic Efficacy of Auger / Conversion Electron (111-In, 140-Nd) vs alpha(213-Bi) or Conventional beta(90-Y, 153-Sm) Emitters.BEHR T.m., et alContributions to Conferences
2012Reduction of Pu(VI) by FeCARBOL Paul, et alContributions to Conferences
2001Separation of 248Cm from a 252Cf Neutron Source for Production of Cm Targets.MALMBECK R., et alArticles in Journals
Showing results 81 to 100 of 139

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top